TCL Archive Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio, by Robert Cook-Deegan June 14, 2013
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
